| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Phio Pharmaceuticals Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.99 |
| 52 Week High | US$29.07 |
| 52 Week Low | US$3.35 |
| Beta | 1.45 |
| 11 Month Change | -36.76% |
| 3 Month Change | -35.08% |
| 1 Year Change | -84.02% |
| 33 Year Change | -97.95% |
| 5 Year Change | -99.83% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Phio Pharmaceuticals appoints interim executive chairman
Sep 29Phio Pharmaceuticals GAAP EPS of -$0.19 beats by $0.12
Aug 11Is Phio Pharmaceuticals (NASDAQ:PHIO) In A Good Position To Deliver On Growth Plans?
Apr 11
Phio soars 22% on positive in vivo data on combination PD-1 and TIGIT therapy in cancer
Nov 09Shareholder Returns
| PHIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.4% | 3.4% | -2.4% |
| 1Y | -84.0% | 17.1% | 17.5% |
Return vs Industry: PHIO underperformed the US Biotechs industry which returned 17.1% over the past year.
Return vs Market: PHIO underperformed the US Market which returned 17.5% over the past year.
Price Volatility
| PHIO volatility | |
|---|---|
| PHIO Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PHIO's share price has been volatile over the past 3 months.
Volatility Over Time: PHIO's weekly volatility has decreased from 20% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 9 | Bob Bitterman | www.phiopharma.com |
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor.
Phio Pharmaceuticals Corp. Fundamentals Summary
| PHIO fundamental statistics | |
|---|---|
| Market cap | US$1.96m |
| Earnings (TTM) | -US$9.38m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs PHIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHIO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$5.35m |
| Gross Profit | -US$5.35m |
| Other Expenses | US$4.03m |
| Earnings | -US$9.38m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -18.38 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PHIO perform over the long term?
See historical performance and comparison